Genprex has chosen Andelyn Biosciences to facilitate the manufacturing scale-up of its innovative gene therapy targeting diabetes. This candidate aims to deliver the Pdx1 and MafA genes directly to the pancreas through the pancreatic duct, utilizing an AAV vector. The initiative seeks to develop a potential treatment for both type 1 and type 2 diabetes.
Transitioning to Clinical-Stage Manufacturing
Through this partnership, Andelyn will oversee the transition of Genprex’s AAV-based diabetes gene therapy candidate. This includes process optimization, scale-up, and manufacturing activities required for IND-enabling and clinical trials.
Andelyn’s Curator® Cell and Gene Therapy Platform will play a crucial role in this collaboration. The company brings significant expertise in AAV process development, technology transfer, analytical development, and cGMP manufacturing. Planned manufacturing activities encompass process optimization, analytical qualification, potency assay development, and the production of drug products in a facility compliant with current Good Manufacturing Practices (cGMP).
Innovative Approach for Type 1 Diabetes
In the context of type 1 diabetes, Genprex’s candidate aims to transform pancreatic alpha cells into functional beta-like cells that can produce insulin. Preclinical studies conducted in mouse models of type 1 diabetes have demonstrated the therapy’s potential to restore normal blood glucose levels over extended periods. Additionally, research involving nonhuman primates has shown reduced insulin requirements, increased C-peptide levels, and enhanced glucose tolerance, suggesting a promising avenue for diabetes management.
Addressing Type 2 Diabetes Challenges
For type 2 diabetes, where autoimmunity is not the predominant concern, Genprex is investigating whether its gene therapy approach can rejuvenate and replenish insulin-producing beta cells that have become exhausted. This represents a significant shift in the treatment paradigm for type 2 diabetes, targeting the underlying cellular dysfunction that contributes to the disease.
Expert Support from Andelyn
Matt Niloff, Chief Commercial Officer at Andelyn, expressed enthusiasm about the partnership. He emphasized the importance of transitioning from academic or research-grade manufacturing to a scalable cGMP process, which is crucial for the successful development of advanced therapies. Andelyn’s team will provide the necessary technical, operational, and quality expertise to establish a solid manufacturing foundation for Genprex’s upcoming preclinical and clinical milestones.
Strategic Move for Genprex
Ryan Confer, President and CEO of Genprex, highlighted the significance of selecting Andelyn for this phase of their diabetes gene therapy program. He noted that Andelyn’s extensive experience in AAV development and cGMP manufacturing will be instrumental as Genprex progresses through the manufacturing process, preparing for IND-enabling studies and future clinical evaluations.
Conclusion
The collaboration between Genprex and Andelyn Biosciences marks a pivotal moment in the development of gene therapies for diabetes. With a strong focus on manufacturing scale-up and optimization, this partnership aims to bring innovative treatments to market, ultimately improving the lives of patients with diabetes. As the project advances, it will pave the way for new therapeutic options in the ever-evolving landscape of diabetes care.
- Key Takeaways:
- Genprex partners with Andelyn for diabetes gene therapy manufacturing.
- The therapy targets gene delivery to the pancreas using an AAV vector.
- Preclinical studies show promising results in both type 1 and type 2 diabetes models.
- Andelyn’s expertise will support the transition to clinical-stage manufacturing.
- This collaboration could lead to significant advancements in diabetes treatment options.
Read more → www.genengnews.com
